Skip to main content
. 2022 Nov 28;10:203. doi: 10.1186/s40168-022-01388-8

Table 2.

Clinical parameters of CRC patients by M5 category

M5 category Low (n = 74) Moderate (n = 206) High (n = 53) P value
Age (years, range) 61 (38–81) 62 (28–87) 68 (40–83) 0.0656
Sex (male/female) 23/51 79/127 22/31 0.4324
BMI (kg/m2) 24.63 ± 2.79 24.33 ± 3.28 24.03 ± 3.33 0.568
Smoking (n, %) 10 (13.5%) 32 (15.5%) 5 (9.4%) 0.08367
Drinking (n, %) 35 (47.3%) 78 (37.9%) 8 (15.1%) 0.001077
ASA classification
 1 27 (36.5%) 70 (34.0%) 13 (24.5%) 0.1786&
 2 44 (59.5%) 122 (59.2%) 32 (60.4%)
 3 3 (4.1%) 14 (6.8%) 8 (15.1%)
CEA-high (n, %) 9 (12.2%) 34 (16.9%) 30 (57.7%) 0.0001248
Comorbidity (n, %) 42 (56.8%) 99 (48.1%) 34 (64.2%) 0.07785
 Hypertension 36 (48.6%) 68 (33%) 22 (41%) 0.04865
 Type 2 diabetes 10 (13.5%) 44 (21.4%) 15 (28.3%) 0.119
 Pulmonary disease 6 (8.1%) 15 (7.3%) 2 (3.8%) 0.644
Medication (n, %) 43 (58.1%) 104 (50.5%) 35 (66.0%) 0.1042
 Anti-hypertensive 31 (42.9%) 71 (34.5%) 24 (45.3%) 0.235
 Anti-diabetic 7 (9.5%) 39 (18.9%) 12 (22.6%) 0.08794
 Anti-inflammatory 7 (9.5%) 24 (11.7%) 11 (20.8%) 0.1477
Tumor location
 Proximal colon 22 (29.7%) 38 (18.4%) 8 (15.1%) 0.09491&
 Distal colon 29 (39.2%) 107 (51.9%) 30 (57.7%)
 Rectum 22 (29.7%) 60 (29.1%) 13 (24.5%)
Tumor stage
 0,1 23 (31.1%) 50 (24.3%) 3 (5.7%) 0.002322&
 2 19 (26.8%) 67 (32.5%) 16 (30.2%)
 3 26 (35.1%) 63 (30.6%) 19 (35.8%)
 4 (M1) 6 (8.1%) 26 (12.6%) 15 (28.3%)
Lym. Inv. (n, %) 18 (24.3%) 62 (30.1%) 18 (34.0%) 0.4769
MSI (n/N, %) 14/66 (21.2%) 23/188 (12.2%) 3/53 (5.7%) 0.00797
K-ras (n, %) 22 (33.3%) 60 (33.0%) 19 (38.0%) 0.8157

The anti-inflammatory drug is nonsteroidal. One-way ANOVA is used for continuous variables. Fisher’s exact test is a default test for comparing categorical variables unless specified otherwise. $ indicates that the variable is unsuitable for Fisher’s exact test and applied to chi-square test. Lym. Inv., lymphatic invasion; MSI, microsatellite instability